GlassScriptPhysician profile
Dion G Miranda
NPI 1972751097
$4,732.43
in general payments reported to CMS, 2019-2025
35 companies · $694 in 2025
The $694 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,686 · 2020: $439 · 2021: $37.44 · 2022: $442 · 2023: $705 · 2024: $729 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,128.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $798.50 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $797.48 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $558.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $454.34 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $394.07 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $323.42 | 2019-2025 | |
| Amgen INC. | $244.05 | 2019-2025 | Evenity, Prolia, Repatha |
| Sanofi-Aventis U.S. LLC | $170.65 | 2019-2022 | |
| Abbvie INC. | $161.47 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $100.72 | 2019-2025 | |
| Astellas Pharma US INC | $69.92 | 2019 | |
| Exact Sciences Corporation | $69.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $66.78 | 2019-2020 | |
| Aytu Biopharma, INC. | $50.69 | 2019 | |
| Janssen Pharmaceuticals, INC | $40.94 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $39.24 | 2020-2024 | Eliquis |
| Abbott Laboratories | $37.03 | 2019-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $34.48 | 2019-2023 | Livalo, Seglentis |
| Allergan, INC. | $30.43 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $27.28 | 2020-2022 | |
| Amarin Pharma, INC. | $26.61 | 2019-2020 | |
| Genentech USA, INC. | $23.80 | 2019 | |
| Ironshore Pharmaceuticals INC. | $21.27 | 2019 | |
| Tris Pharma INC | $21.24 | 2024 | Dyanavel Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $20.61 | 2022 | |
| Hologic Sales and Service, LLC | $17.99 | 2025 | Third Wave, Thinprep 2000 Processor, Aptima |
| Sumitomo Pharma America, INC. | $17.24 | 2023 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $16.86 | 2024 | Voquezna |
| Sunovion Pharmaceuticals INC. | $16.55 | 2022 | |
| Hikma Pharmaceuticals USA | $16.37 | 2023 | Mitigare |
| Currax Pharmaceuticals LLC | $14.41 | 2022 | |
| Shire North American Group INC | $13.02 | 2019 | |
| Adlon Therapeutics L.P. | $12.43 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $12.34 | 2021 | |
| Dexcom, INC. | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dion Miranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.